How Eli Lilly (LLY) Balances Dividend Payouts With Long-Term Innovation

Core Insights - Eli Lilly and Company (NYSE: LLY) is recognized as one of the 11 Best Value Dividend Stocks to buy currently [1] - The company has a long-standing history in developing drugs for various conditions, including diabetes, cancer, and immunology [2] Financial Performance - In the second quarter, Eli Lilly generated revenue of $15.6 billion, with three key products—Mounjaro, Zepbound, and Verzenio—accounting for 65% of this revenue [3] - Revenue growth for these products ranged from 12% to 172%, highlighting their significant contribution to sales momentum [3] Research and Development - Eli Lilly's research and development expenses increased by 23% year-over-year, reaching $3.3 billion in the second quarter, which constitutes over 21% of the company's total revenue [4] Shareholder Returns - The company has consistently returned value to shareholders, having raised its dividends for 11 consecutive years, with a current quarterly dividend of $1.50 per share [5] - As of September 26, the stock has a dividend yield of 0.83% [5]